Literature DB >> 12031859

Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative.

Feng C Zhou1, Klaus-Peter Lesch, Dennis L Murphy.   

Abstract

Monoamine neurons are believed to use neuronal-specific transporters to remove their own transmitters from the extracellular space and thus terminate transmission to postsynaptic neurons. We report here, for the first time, conclusive evidence that a cross clearance of serotonin into dopamine neurons exists. Such alternative uptake by different neurons is adopted under circumstances when their own transporter function is no longer adequate. When the serotonin transporter (5-HTT) is disrupted in 5-HTT knockout mice, serotonin (5-HT) is found in dopamine (DA) neurons of homozygous (-/-) but not of heterozygous (+/-) mutant mice or their normal littermates. DA neurons containing 5-HT are seen in the substantia nigra and ventral tegmental area (VTA), but not in other brain areas of 5-HTT -/- mice. Normal rats treated with a 5-HT uptake blocker paroxetine also showed similar result. To verify the role of the DA transporter in such ectopic uptake, 5-HTT -/- mice were treated with DA uptake blocker GBR-12935, ectopic 5-HT in DA neurons was disappeared. These data indicate that: (a) 5-HT can be taken into DA neurons in rats and mice when the 5-HTT is not functionally adequate to remove extracellular 5-HT; (b) the 5-HT uptake into DA neurons is not affected by the 5-HT uptake blocker paroxetine; and (c) the DA transporter is responsible for the 5-HT uptake into DA neurons. This study thus demonstrates that cross neuronal type uptake exists and serves as a compensatory backup when a specific transporter is dysfunctional. This study also demonstrates that DA neurons can store 5-HT for possible "false neurotransmitter" or other usage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12031859     DOI: 10.1016/s0006-8993(02)02709-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  37 in total

1.  Behavioral training reverses global cortical network dysfunction induced by perinatal antidepressant exposure.

Authors:  Xiaoming Zhou; Jordan Y-F Lu; Ryan D Darling; Kimberly L Simpson; Xiaoqing Zhu; Fang Wang; Liping Yu; Xinde Sun; Michael M Merzenich; Rick C S Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

2.  Dissociable roles of dopamine and serotonin transporter function in a rat model of negative urgency.

Authors:  Justin R Yates; Mahesh Darna; Cassandra D Gipson; Linda P Dwoskin; Michael T Bardo
Journal:  Behav Brain Res       Date:  2015-05-21       Impact factor: 3.332

3.  Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours.

Authors:  T Lee Gilman; Christina M George; Melissa Vitela; Myrna Herrera-Rosales; Mohamed S Basiouny; Wouter Koek; Lynette C Daws
Journal:  Eur J Neurosci       Date:  2018-05-24       Impact factor: 3.386

Review 4.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

Review 5.  A pharmacological analysis of mice with a targeted disruption of the serotonin transporter.

Authors:  Meredith A Fox; Anne M Andrews; Jens R Wendland; Klaus-Peter Lesch; Andrew Holmes; Dennis L Murphy
Journal:  Psychopharmacology (Berl)       Date:  2007-08-22       Impact factor: 4.530

6.  Quinine enhances the behavioral stimulant effect of cocaine in mice.

Authors:  Adriana Huertas; William D Wessinger; Yuri V Kucheryavykh; Priscila Sanabria; Misty J Eaton; Serguei N Skatchkov; Legier V Rojas; Gerónimo Maldonado-Martínez; Mikhail Y Inyushin
Journal:  Pharmacol Biochem Behav       Date:  2014-12-05       Impact factor: 3.533

Review 7.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

Review 8.  Identifying essential cell types and circuits in autism spectrum disorders.

Authors:  Susan E Maloney; Michael A Rieger; Joseph D Dougherty
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

9.  Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans.

Authors:  M A Fox; M G Panessiti; P R Moya; T J Tolliver; K Chen; J C Shih; D L Murphy
Journal:  Pharmacogenomics J       Date:  2012-09-11       Impact factor: 3.550

10.  Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders.

Authors:  Lynette C Daws; Wouter Koek; Nathan C Mitchell
Journal:  ACS Chem Neurosci       Date:  2013-01-16       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.